NewsRx

Search our medical news database

Cancer Vaccines

Tumor-Specific Vaccines Under Development

Published in Vaccine Weekly, January 24th, 2001

BioPulse International, Inc., (BIOP), San Ysidro, California, announced the development of multiple Tumor-Specific Cancer Vaccines (TSV).

The vaccines are based on the company's dendritic cell cancer vaccine technology. These vaccines will potentially offer additional alternatives to cancer patients.

Cancer vaccines that have been under investigation by BioPulse previously used only patient-specific tumor antigens. This approach provides a customized and specific vaccine product for each patient. The new tumor-specific vaccines use a combination of tumor antigens designed to target a class of tumors. This strategy potentially allows for a single...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook